Hemab Therapeutics (NASDAQ:COAG) Reaches New 12-Month High Following Analyst Upgrade

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG)’s share price reached a new 52-week high during mid-day trading on Wednesday after HC Wainwright raised their price target on the stock from $52.00 to $60.00. HC Wainwright currently has a buy rating on the stock. Hemab Therapeutics traded as high as $54.19 and last traded at $53.31, with a volume of 101491 shares changing hands. The stock had previously closed at $51.74.

COAG has been the topic of a number of other research reports. Wedbush reissued an “outperform” rating and issued a $55.00 price target (up from $42.00) on shares of Hemab Therapeutics in a research note on Monday, July 13th. Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a report on Wednesday, May 27th. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price objective on the stock. Finally, Jefferies Financial Group increased their price target on Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Hemab Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $51.40.

Insider Transactions at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the stock in a transaction on Tuesday, June 16th. The shares were purchased at an average price of $24.98 per share, for a total transaction of $1,536,844.54. Following the transaction, the insider directly owned 6,444,637 shares of the company’s stock, valued at approximately $160,987,032.26. This represents a 0.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders acquired 72,467 shares of company stock valued at $1,809,595.

Hemab Therapeutics Stock Performance

The business has a 50-day moving average of $37.46. The company has a market capitalization of $2.50 billion and a price-to-earnings ratio of -2.24.

Hemab Therapeutics (NASDAQ:COAG) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.17). On average, sell-side analysts anticipate that Hemab Therapeutics Holdings, Inc. will post -2.89 earnings per share for the current fiscal year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.